N/A N=154 GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry
Aortic Aneurysm, Thoracic · Descending Thoracic Aortic Dissection · Aortic Diseases
Primary: Number of Subjects With All-cause Mortality (Long-term) — 31 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=186 Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term
Obesity · Induction of Labor Affected Fetus / Newborn
Primary: Number of Participants With Cesarean Delivery — 27; 37 Participants
N/A N=5,389 Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project)
Patient Adherence
Primary: Percentage of Women With Triage Pap Smears at 120 Days After HPV Results — 314; 163 Participants
Phase 4 N=30 Progestin-Only Pill Use and Breastfeeding Study
Contraception · Breastfeeding
Primary: Exclusive Lactation Among Birthing People at 8 Weeks Postpartum. — 7; 7; 6 Participants
N/A N=24 A Comparison Between GUMMETAL and SS Orthodontic Wires in Space Closure
Malocclusion, Angle Class I
Primary: Total Amount of Canine Retraction — 3.41; 3.71 mm
N/A N=10 Basic Assessment of Safety and Minimally Invasive Stimulation Via Injectrode
Chronic Lower Limb Pain
Primary: Safety - Number of Participants With Device-Related Adverse Events & Histological Analysis — 0 Participants
Phase 1 N=20 Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment
Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of Sotorasib — 5080; 4850; 7250 ng/mL
N/A N=13 Clinical Study to Evaluate the Sun Protection Factor (SPF) of Three Sunscreen Products
Sunscreening Agents
Primary: Arithmetic Mean SPF Values — 29.2; 16.4; 28.2; 16.4 Ratio
N/A N=9 Narrative Exposure Therapy (NET)
Posttraumatic Stress Disorder
Primary: PTSD Checklist for the DSM-5 (PCL-5) — 47.8; 25.0; 20; -22.8 units on a scale
Phase 1 N=7 S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)
RYR-1 Myopathy
Primary: Number of Participants Experiencing Adverse Events When Treated With S48168 (ARM210) — 0; 0; 0; 0 Participants
Phase 1 N=30 Crossover, Single Dose Randomized, Bioequivalence of Ketoprofen Lysine Salt Immediate Release vs Oral Solution
Pain Disorders
Primary: Ketoprofen Plasma PK Parameters: Cmax — 3.61; 3.40 μg/mL — p=0.1455
Phase 2 N=36 A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 9; 5; 10; 5 Participants
Phase 2 N=10 Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab
Atopic Dermatitis
Primary: Proportion of Patients Who Achieve an Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16. — 2 Participants
N/A N=1,798 Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
Idiopathic Pulmonary Fibrosis
Primary: Adherence Trajectories to Nintedanib Among Idiopathic Pulmonary Fibrosis (IPF) Patients — 781; 202; 190; 255 Participants
N/A N=22,054 Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
Osteoporosis, Postmenopausal
Primary: Number of Participants With a Nonvertebral Fracture — 313; 333 Participants